Trevi Therapeutics (TRVI) Scheduled to Post Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) is scheduled to announce its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). On average, analysts expect Trevi Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Trevi Therapeutics Stock Up 1.5 %

Trevi Therapeutics stock traded up $0.04 during mid-day trading on Tuesday, hitting $2.65. The company’s stock had a trading volume of 100,654 shares, compared to its average volume of 250,764. Trevi Therapeutics has a twelve month low of $0.97 and a twelve month high of $4.00. The stock’s fifty day moving average price is $2.76 and its two-hundred day moving average price is $2.68. The stock has a market capitalization of $186.64 million, a P/E ratio of -7.59 and a beta of 1.00.

Wall Street Analyst Weigh In

TRVI has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, May 8th. Rodman & Renshaw started coverage on Trevi Therapeutics in a research note on Thursday, June 13th. They issued a “buy” rating and a $7.00 target price on the stock.

Insider Activity

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 25,037 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $2.86, for a total value of $71,605.82. Following the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at $610,075.18. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Thomas Sciascia sold 53,368 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $2.55, for a total value of $136,088.40. Following the completion of the transaction, the insider now owns 214,433 shares of the company’s stock, valued at approximately $546,804.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jennifer L. Good sold 25,037 shares of the stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $2.86, for a total value of $71,605.82. Following the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at approximately $610,075.18. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 87,333 shares of company stock valued at $232,454. Insiders own 24.37% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.